Arrowhead Pharmaceuticals
ARWR · Biotechnology
$58.02
0.6%Harmony Biosciences
HRMY · Biotechnology
$36.13
0.3%The short version
- Harmony Biosciences is the larger business, with $869M of revenue in fiscal 2025 against $829M for Arrowhead Pharmaceuticals.
- Arrowhead Pharmaceuticals grew revenue faster (23,258.2%, against 21.5%).
- Harmony Biosciences kept more of each dollar of sales as operating profit (24.0% operating margin, against 11.9% operating margin).
- Harmony Biosciences turned more of its sales into free cash flow (40.1% FCF margin, against 18.9% FCF margin).
| Latest fiscal year | ARWR · FY25 | HRMY · FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.3B | $2.1B |
| Revenue | $829M | $869M |
| Free cash flow | $157M | $348M |
| Net income | −$1.6M | $159M |
| Growth | ||
| Revenue growth | 23,258.2% | 21.5% |
| 5-year growth | 56.6% | 40.3% |
| Share count change | 11.7% | 1.2% |
| Profitability | ||
| Gross margin | — | 77.2% |
| Operating margin | 11.9% | 24.0% |
| Net margin | −0.2% | 18.3% |
| FCF margin | 18.9% | 40.1% |
| Return on capital | — | 48.9% |
| Return on equity | −0.5% | 20.8% |
| Balance sheet | ||
| Net debt | −$665M | −$612M |
| Net debt / EBITDA | −5.5x | — |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | — | 11.7x |
| Piotroski F-score | 5 | 5 |
FY16
ARWR $0.2M
HRMY —
FY17
ARWR $31.4M
HRMY —
FY18
ARWR $16.1M
HRMY —
FY19
ARWR $169M
HRMY $6.0M
FY20
ARWR $88.0M
HRMY $160M
FY21
ARWR $138M
HRMY $305M
FY22
ARWR $243M
HRMY $438M
FY23
ARWR $241M
HRMY $582M
FY24
ARWR $3.6M
HRMY $715M
FY25
ARWR $829M
HRMY $869M
ARWR
HRMY
FY16
ARWR −51,627.1%
HRMY —
FY17
ARWR −117.8%
HRMY —
FY18
ARWR −346.5%
HRMY —
FY19
ARWR 36.3%
HRMY −2,433.8%
FY20
ARWR −105.9%
HRMY 10.6%
FY21
ARWR −107.8%
HRMY 28.7%
FY22
ARWR −73.4%
HRMY 27.5%
FY23
ARWR −85.2%
HRMY 33.0%
FY24
ARWR −16,927.1%
HRMY 26.7%
FY25
ARWR 11.9%
HRMY 24.0%
ARWR
HRMY
FY16
ARWR −$68.3M
HRMY —
FY17
ARWR −$31.9M
HRMY —
FY18
ARWR −$48.6M
HRMY —
FY19
ARWR $161M
HRMY −$75.6M
FY20
ARWR −$108M
HRMY −$3.0M
FY21
ARWR $148M
HRMY $98.3M
FY22
ARWR −$189M
HRMY $144M
FY23
ARWR −$331M
HRMY $219M
FY24
ARWR −$604M
HRMY $219M
FY25
ARWR $157M
HRMY $348M
ARWR
HRMY
FY16
ARWR —
HRMY —
FY17
ARWR −82.4%
HRMY —
FY18
ARWR −70.2%
HRMY —
FY19
ARWR 136.1%
HRMY —
FY20
ARWR −57.6%
HRMY —
FY21
ARWR −71.2%
HRMY 78.2%
FY22
ARWR −69.1%
HRMY 57.8%
FY23
ARWR −167.1%
HRMY 49.3%
FY24
ARWR —
HRMY 42.7%
FY25
ARWR —
HRMY 48.9%
ARWR
HRMY
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.